Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) shares fell 3.1% during trading on Friday . The company traded as low as $22.58 and last traded at $22.62, with a volume of 498,183 shares trading hands. The stock had previously closed at $23.35.

A number of research firms have recently commented on SUPN. Jefferies Group reaffirmed a “buy” rating and set a $28.00 price objective (up previously from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Northland Securities downgraded shares of Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a research report on Monday, July 18th. Finally, Piper Jaffray Cos. downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price for the company. in a research report on Monday, July 18th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Supernus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $24.50.

The stock has a 50 day moving average price of $21.45 and a 200-day moving average price of $17.19. The firm has a market capitalization of $1.12 billion and a PE ratio of 46.29.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.05. The firm had revenue of $50.40 million for the quarter, compared to the consensus estimate of $49.67 million. During the same period in the prior year, the business earned $0.03 EPS. The company’s quarterly revenue was up 43.6% compared to the same quarter last year. On average, analysts expect that Supernus Pharmaceuticals Inc. will post $0.67 earnings per share for the current year.

In related news, CFO Gregory S. Patrick sold 3,395 shares of the stock in a transaction on Thursday, July 14th. The stock was sold at an average price of $22.00, for a total value of $74,690.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Other institutional investors recently added to or reduced their stakes in the company. New York State Common Retirement Fund raised its position in Supernus Pharmaceuticals by 3.7% in the fourth quarter. New York State Common Retirement Fund now owns 205,981 shares of the specialty pharmaceutical company’s stock worth $2,768,000 after buying an additional 7,299 shares during the period. Cornerstone Capital Management Holdings LLC. raised its position in Supernus Pharmaceuticals by 15.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 123,600 shares of the specialty pharmaceutical company’s stock worth $1,662,000 after buying an additional 16,300 shares during the period. Finally, Marshall Wace LLP bought a new position in Supernus Pharmaceuticals during the fourth quarter worth $2,345,000.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.